A Receptor Mutation Did Not Delay THC Tolerance in a Chemotherapy-Neuropathy Model
A cannabinoid-receptor mutation associated with altered tolerance in other experiments did not delay THC tolerance in mice with cisplatin-related neuropathy. The result shows why a mechanism demonstrated in one pain model may not transfer to another.
A chronic pain model with two sexes
Researchers studied wild-type mice and animals carrying a desensitization-resistant CB1 receptor mutation. Cisplatin induced mechanical hypersensitivity, and repeated THC was evaluated using paw-withdrawal responses. This was animal research, not a trial treating people with chemotherapy-related pain.
The genotype result was negative
The mutation did not significantly change sensitivity or tolerance to THC under the tested conditions. Females showed faster loss of the anti-allodynic response in selected dose comparisons. That sex-related pattern does not turn the genotype result positive or establish one universal tolerance timeline.
Receptor blocking added context
A CB1 antagonist fully blocked THC’s anti-allodynic effect, while a CB2 inverse agonist partially blocked it. These findings support contributions from receptor pathways within this model; they do not identify a single exclusive mechanism governing every pain response.
Why the model matters
The mice received chemotherapy to induce neuropathy but did not have the preceding cancer condition experienced by clinical patients. Paw responses, injected dosing and the specific mutation further limit translation. A claim that preventing CB1 desensitization must preserve cannabis pain relief is therefore too broad. The paper supports testing that proposition in the actual disease model rather than assuming that an earlier mechanistic result guarantees benefit.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Henderson-Redmond AN; Crawford LC; Sepulveda DE; Hale DE; Lesperance JJ; Morgan DJ. Sex Differences in Tolerance to Delta-9-Tetrahydrocannabinol in Mice With Cisplatin-Evoked Chronic Neuropathic Pain. Frontiers in molecular biosciences (2021). DOI: 10.3389/fmolb.2021.684115.
